Vaccination strategies for Korean patients with inflammatory bowel disease

1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390:2769–2778.
crossref pmid
2. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111–119.
crossref pmid pmc
3. Low D, Swarup N, Okada T, Mizoguchi E. Landscape of inflammatory bowel disease in Singapore. Intest Res 2022;20:291–296.
crossref pmid pmc pdf
4. Manser CN, Maillard MH, Rogler G, et al. Vaccination in patients with inflammatory bowel diseases. Digestion 2020;101(Suppl 1):58–68.
crossref pmid pmc pdf
5. Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med 2018;33:28–35.
crossref pmid pmc pdf
6. Jung YS, Han M, Park S, Cheon JH. Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study. Korean J Intern Med 2020;35:1104–1113.
crossref pmid pmc pdf
7. Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20–27.
crossref pmid pmc pdf
8. Hong SW, Park J, Yoon H, et al. Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease. Korean J Intern Med 2021;36(Suppl 1):S9–S17.
crossref pmid pmc pdf
9. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020;14:4–22.
pmid
10. Park J. Which biologic agents increase perioperative complications in patients with inflammatory bowel disease? Intest Res 2022;20:1–2.
crossref pmid pmc pdf
11. Singh A, Mahajan R, Kedia S, et al. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11–30.
crossref pmid pmc pdf
12. Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res 2022;Mar. 11. [Epub]. https://doi.org/10.5217/ir.2021.00154 .
crossref pmid
13. Benchimol EI, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for immunizations in patients with inflammatory bowel disease (IBD)-Part 1: live vaccines. Gastroenterology 2021;161:669–680.
crossref pmid
14. Jones JL, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for immunizations in patients with inflammatory bowel disease (IBD)-Part 2: inactivated vaccines. Gastroenterology 2021;161:681–700.
crossref pmid
15. Kucharzik T, Ellul P, Greuter T, et al. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis 2021;15:879–913.
crossref pmid pdf
16. Caldera F, Hayney MS, Farraye FA. Vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2020;115:1356–1361.
crossref pmid
17. Wasan SK, Calderwood AH, Long MD, Kappelman MD, Sandler RS, Farraye FA. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis 2014;20:246–250.
pmid
18. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68(Suppl 3):s1–s106.
crossref pmid pmc
19. Tan B, Ong D. Pediatric to adult inflammatory bowel disease transition: the Asian experience. Intest Res 2020;18:11–17.
crossref pmid pmc pdf
20. Horton HA, Kim H, Melmed GY. Vaccinations and immunoprophylaxis in gastrointestinal and liver disorders. In: McNally PR, ed. GI/Liver Secrets Plus. 5th ed. Philadelphia (PA): Elseviser, 2015;155–160. 21. Zullow S, Farraye FA. Updates on vaccinating the inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2019;13:229–239.
crossref pmid
22. Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004;82:488–496.
crossref pmid pdf
23. Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Buhler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation: a systematic review of randomized trials, observational studies and case reports. Vaccine 2017;35:1216–1226.
crossref pmid
24. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:309–318.
crossref pmid pdf
25. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241–258.
crossref pmid pdf
26. Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol 2018;16:1919–1927.
crossref pmid
27. The Korean Society of Infectious Diseases. Vaccinations for Adults. 3rd ed. Seoul (KR): Koonja Publishing Inc, 2019. 29. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:420–429.
crossref pmid pmc
30. Caldera F, Hayney MS, Cross RK. Using number needed to harm to put the risk of herpes zoster from tofacitinib in perspective. Inflamm Bowel Dis 2019;25:955–957.
crossref pmid
31. Tinsley A, Navabi S, Williams ED, et al. Increased risk of influenza and influenza-related complications among 140,480 patients with inflammatory bowel disease. Inflamm Bowel Dis 2019;25:369–376.
crossref pmid
32. Hagihara Y, Ohfuji S, Watanabe K, et al. Infliximab and/or immunomodulators inhibit immune responses to trivalent influenza vaccination in adults with inflammatory bowel disease. J Crohns Colitis 2014;8:223–233.
crossref pmid
33. Launay O, Abitbol V, Krivine A, et al. Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: a two-year prospective study. J Crohns Colitis 2015;9:1096–1107.
crossref pmid
34. Melmed GY, Rubin DT, McGovern DP. Winter is coming!: clinical, immunologic, and practical considerations for vaccinating patients with inflammatory bowel disease during the coronavirus disease-2019 pandemic. Gastroenterology 2021;160:639–644.
crossref pmid pmc
35. Lee YJ, Kim SE, Park YE, et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID. Intest Res 2022;20:171–183.
crossref pmid pmc pdf
36. Long MD, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:240–248.
crossref pmid pmc pdf
37. Kantso B, Simonsen J, Hoffmann S, Valentiner-Branth P, Petersen AM, Jess T. Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977–2013. Am J Gastroenterol 2015;110:1582–1587.
crossref pmid pdf
38. Case DJ, Copeland LA, Stock EM, Herrera HR, Pfanner TP. Pneumococcal vaccination rates in VHA patients with inflammatory bowel disease. Medicine (Baltimore) 2015;94:e417.
crossref pmid pmc
39. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010;105:148–154.
crossref pmid pdf
40. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis 2012;18:261–268.
crossref pmid pmc
41. Yim SY, Kim JH. The epidemiology of hepatitis B virus infection in Korea. Korean J Intern Med 2019;34:945–953.
crossref pmid pmc pdf
42. Papa A, Felice C, Marzo M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. J Crohns Colitis 2013;7:113–119.
crossref pmid
43. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57–63.
crossref pmid pdf
44. Harsh P, Gupta V, Kedia S, et al. Prevalence of hepatitis B, hepatitis C and human immunodeficiency viral infections in patients with inflammatory bowel disease in north India. Intest Res 2017;15:97–102.
crossref pmid pmc pdf
45. Kim ES. Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia. Intest Res 2017;15:5–6.
crossref pmid pmc pdf
46. Yeo SJ, Lee HS, Jang BI, et al. Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease. Intest Res 2018;16:400–408.
crossref pmid pmc pdf
47. Kim ES, Cho KB, Park KS, et al. Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J Clin Gastroenterol 2014;48:553–558.
pmid
48. Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010;59:1340–1346.
crossref pmid
49. Lee JM, Wei SC, Lee KM, et al. Clinical course of hepatitis B viral infection in patients undergoing anti-tumor necrosis factor α therapy for inflammatory bowel disease. Gut Liver 2022;16:396–403.
crossref pmid pmc
50. Park SK, Choi CH, Chun J, et al. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res 2020;18:18–33.
crossref pmid pmc pdf
51. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009;132:331–335.
pmid
52. Caldera F, Saha S, Wald A, et al. Lower sustained diphtheria and pertussis antibody concentrations in inflammatory bowel disease patients. Dig Dis Sci 2018;63:1532–1540.
crossref pmid pdf
53. Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 2017;35:2633–2641.
crossref pmid
54. Hong HS, Jung J, Park SH, et al. Seroprevalence of viral infectious diseases and associated factors in Korean patients with inflammatory bowel diseases. Korean J Intern Med 2022;37:73–84.
crossref pmid pmc pdf
55. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019;68:698–702.
crossref pmid pmc
56. Crosby S, Schuh MJ, Caldera F, Farraye FA. Vaccination of patients with inflammatory bowel disease during the COVID-19 pandemic. Gastroenterol Hepatol (N Y) 2021;17:18–30. 57. Jacobson DL, Bousvaros A, Ashworth L, et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:1441–1449.
crossref pmid pmc
58. Dezfoli S, Horton HA, Thepyasuwan N, et al. Combined immunosuppression impairs immunogenicity to tetanus and pertussis vaccination among patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:1754–1760.
crossref pmid
59. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2392–2403.
crossref pmid
60. Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn’s disease. Am J Gastroenterol 2004;99:2503–2504.
crossref pmid
61. Marin AC, Gisbert JP, Chaparro M. Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease. World J Gastroenterol 2015;21:11273–11281.
crossref pmid pmc
62. Freedman M, Kroger A, Hunter P, Ault KA, Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2020. Ann Intern Med 2020;172:337–347.
crossref pmid
63. Nugent Z, Singh H, Targownik LE, Bernstein CN. Herpes zoster infection and herpes zoster vaccination in a population-based sample of persons with IBD: is there still an unmet need? Inflamm Bowel Dis 2019;25:532–540.
crossref pmid
64. Chang K, Lee HS, Kim YJ, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clin Gastroenterol Hepatol 2018;16:1928–1936.
crossref pmid
65. Soh H, Chun J, Han K, et al. Increased risk of herpes zoster in young and metabolically healthy patients with inflammatory bowel disease: a nationwide population-based study. Gut Liver 2019;13:333–341.
crossref pmid pmc
66. Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 2018;24:2258–2265.
crossref pmid pmc
67. Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s disease. J Crohns Colitis 2020;14:23–32.
crossref pmid pdf
68. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66:839–851.
crossref pmid pmc
69. James SF, Chahine EB, Sucher AJ, Hanna C. Shingrix: the new adjuvanted recombinant herpes zoster vaccine. Ann Pharmacother 2018;52:673–680.
crossref pmid pdf
70. Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis 2015;211:1279–1287.
crossref pmid pmc
71. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis 2020;70:181–190.
pmid
73. Lee YJ, Kim KO, Kim MC, et al. Perceptions and behaviors of patients with inflammatory bowel disease during the COVID-19 crisis. Gut Liver 2022;16:81–91.
crossref pmid pmc
74. Kim KO, Jang BI. Management of inflammatory bowel disease in the COVID-19 era. Intest Res 2022;20:3–10.
crossref pmid pmc pdf
75. Hadi Y, Dulai PS, Kupec J, et al. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: propensity matched research network analysis. Aliment Pharmacol Ther 2022;55:191–200.
crossref pmid pdf
76. Singh AK, Jena A, Kumar-M P, Jha DK, Sharma V. Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res 2022;20:134–143.
crossref pdf
77. Barbosa da Luz B, de Oliveira NM, Franca Dos Santos IW, et al. An overview of the gut side of the SARS-CoV-2 infection. Intest Res 2021;19:379–385.
crossref pmid pmc pdf
78. Alexander JL, Moran GW, Gaya DR, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol 2021;6:218–224.
crossref
79. Siegel CA, Melmed GY, McGovern DP, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021;70:635–640.
crossref
80. Botwin GJ, Li D, Figueiredo J, et al. Adverse events after SARSCoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol 2021;116:1746–1751.
crossref pmid pmc
81. Lev-Tzion R, Focht G, Lujan R, et al. COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation. Clin Gastroenterol Hepatol 2022;20:e1263–e1282.
crossref pmid pmc
82. Kennedy NA, Lin S, Goodhand JR, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAd-Ox1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut 2021;70:1884–1893.
crossref pmid pmc
83. Lin S, Kennedy NA, Saifuddin A, et al. Antibody decay, T cell immunity and breakthrough infections following two SARSCoV- 2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun 2022;13:1379.
pmid pmc

留言 (0)

沒有登入
gif